Platforms
CD BioGlyco is a pioneering biotechnology firm that has engineered and refined an array of research platforms focused on glycobiology. Glycobiology is defined as the study of the structure, biosynthesis, and biological functions of glycans and saccharide conjugates (including glycoproteins, glycolipids, proteoglycans, etc.), as well as protein-glycan interactions. Glycogenomics, glycoproteomics, glycomics, and geoinformatics help us better understand the various cellular events involved in saccharides and the role of glycans in diseases. In the production of biological agents, glycans also affect the therapeutic properties of protein drugs and their immune responses.
Fig.1 Influence of glycans and glycan-binding proteins in death receptor signaling and function. (Zol-Hanlon & Schumann, 2020)
To facilitate clients in exploring the multifaceted dimensions of glycobiology research, CD BioGlyco endeavors to provide extensive platforms. These diverse platforms have made available an array of sophisticated analytical methodologies and data analysis techniques tailored for glycobiological investigations. Our goal is to offer a wide range of services, enabling clients to explore the intricate world of glycobiology with thoroughness and precision. Our first-class technology platforms and experienced scientists provide clients with high-precision, high-efficiency, and high-throughput services.
At CD BioGlyco, we also have a range of ready-made Products for selection. These products greatly assist clients in their various glycobiology research. Our products are distinguished by their outstanding quality, supported by strong guarantees, and are adaptable to fulfill the requirements of multiple industries. Our products encompass, but are not limited to:
On the whole, CD BioGlyco has provided a large number of advanced analysis techniques and data analysis tools for glycobiology research. Glyco™ synthesis platform helps to synthesize a variety of glycoconjugates. Glycomics results are combined with other "omics data sets" to gain a deeper understanding and insight into the nature of glycosylation in complex cellular processes. Through our glycoproteomics platform, we identify, classify, quantify, and characterize glycoproteins. The glycobiology microarray platform is widely used to analyze the entire glycogen group and glycosylase under pathological conditions. Glyco™ vaccine development helps accelerate vaccine development and preclinical research. The glycoengineering platform is an important strategy for improving the safety, consistency, and reduced immunogenicity of biological drugs.
Technology: Solid-phase synthesis, Chemical-enzymatic synthesis, Catch and release strategy, Glycan microarray
Journal: Frontiers in Chemistry
IF: 5.5
Published: 2020
Results: This scholarly review delves into recent strides in chemo-enzymatic methodologies aimed at fabricating precisely structured N-glycans, pivotal for comprehending protein functionalities and fostering innovative therapeutic avenues. The authors describe advancements in substrate formulation, glycosyltransferase characterization, and the synthesis of high-mannose, hybrid, and complex N-glycan varieties, underscoring the synergistic benefits of amalgamating chemical and enzymatic approaches to realize efficient and precise N-glycan synthesis. It also probes emergent prospects such as automated synthesis technologies, underscoring their potential applications in refining glycoprotein formulation and advancing biomarker delineation. Ultimately, the authors describe these methodologies’ potential to catalyze paradigm shifts in N-glycan exploration and therapeutic interventions.
Fig.2 Typical glycosyltransferases and glycosidases for the enzymatic synthesis of high-mannose, hybrid, and complex-type N-glycans. (Chao, et al., 2020)
CD BioGlyco is a global biotechnology company that has accomplished several successful glycobiology projects. Firmly anchored in a steadfast commitment to excellence, CD BioGlyco combines profound expertise with state-of-the-art platforms, fostering unparalleled confidence in its capacity to meet the most exacting demands. Spanning a spectrum of integrated glyco-biotechnology platforms, its cadre of researchers is perpetually pioneers within life sciences, pharmaceuticals, and allied sectors. Esteemed for delivering premium solutions, we have become a good partnership grounded in trust and reliability. CD BioGlyco continues to drive advancements in glyco-related studies, playing a pivotal role in unlocking discoveries and understanding complex biological processes. Our technology platforms are constantly updated to meet the latest needs of our global clients. Our only goal is to provide high-quality services while saving time and effort for clients. If you are interested in our services, please contact us for more detailed information.
References
